Home Cart Sign in  
Chemical Structure| 118159-48-1 Chemical Structure| 118159-48-1

Structure of Bicyclol
CAS No.: 118159-48-1

Chemical Structure| 118159-48-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Bicyclol (SY 801) is an orally active compound with anti-HBV and anti-HCV properties.

Synonyms: SY801

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Bicyclol

CAS No. :118159-48-1
Formula : C19H18O9
M.W : 390.34
SMILES Code : O=C(C1=CC(OC)=C(OCO2)C2=C1C3=C4OCOC4=C(OC)C=C3CO)OC
Synonyms :
SY801
MDL No. :MFCD00889471

Safety of Bicyclol

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H302-H361-H372-H410
Precautionary Statements:P201-P264-P280-P301+P330+P331-P312
Class:9
UN#:3077
Packing Group:

Isoform Comparison

Biological Activity

Description
Bicyclol (SY 801), an anti-hepatitis medication, has demonstrated effectiveness in reducing elevated serum transaminases (ALT, AST) by about 50% in patients with chronic hepatitis B and C. It also exhibits a capacity to inhibit replication of HBV and HCV. No significant adverse reactions have been noted. When used in combination with interferon alpha, lamivudine, and adefovir dipivoxil for treating HBV or HCV, bicyclol may enhance antiviral efficacy and reduce YMDD mutants and side effects. In 2004, the China FDA approved bicyclol for production, and since then, it has been extensively employed to treat chronic HBV and HCV in China[1].

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03680183 - Recruiting December 31, 2021 China, Guangdong ... More >> Affiliated Cancer Hospital & Institute of Guangzhou Medical University Recruiting Guangzhou, Guangdong, China, 510182 Contact: Wenying Shu, PhD    86-20-66673666 ext 2006    790840799@qq.com    Contact: Tiantian Cheng, MD    86-20-66673677    gyzlgcp@163.com Less <<
NCT02961413 - Recruiting December 2018 China ... More >> Renji hospital Recruiting Shanghai, China Contact: Yimin Mao Less <<
NCT02944552 Drug-Induced Acute Liver Injur... More >>y Less << Phase 2 Recruiting August 2019 China, Beijing ... More >> Beijing Chest Hospital, Capital Medical University Recruiting Beijing, Beijing, China, 101149 Contact: Naihui Chu          China, Fujian Fuzhou General Hospital of Nanjing Military Command Recruiting Fuzhou, Fujian, China, 350025 Contact: Dongliang Li          China, Shanghai Renji Hospital ,Shanghai Jiao Tong University School of Medicine Recruiting Shanghai, Shanghai, China, 200127 Contact: Yimin Mao    13003175438    maoym11968@163.com    No.85 hospital of PLA Recruiting Shanghai, Shanghai, China Contact: Chengwei Chen    13901989118    ccw2@163.com Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.56mL

0.51mL

0.26mL

12.81mL

2.56mL

1.28mL

25.62mL

5.12mL

2.56mL

References

 

Historical Records

Categories